Senator Bernie Sanders challenged Novo Nordisk CEO Lars Fruergaard Jorgensen in Congress, demanding to know if he found it morally acceptable that high drug prices could lead to 40,000 deaths each year.
In the hearing, Jorgensen defended high prices by stating that reducing drug prices could negatively impact patient access, referencing past instances where insulin price cuts limited patient options.
Senator Sanders announced that he received written commitments from major pharmacy benefit managers, indicating that they would maintain coverage if Novo lowered the prices of Ozempic and Wegovy.
Despite Jorgensen's warnings about the consequences of lowering list prices, Senator Sanders argued that current price points create unnecessary barriers to life-saving treatments for many Americans.
Collection
[
|
...
]